
BioNTech reports high efficacy of COVID-19 vaccine
BioNTech/Pfizer are the first COVID-19 vaccine developers who provided the definitive proof-of-concept that it is possible to protect people from an...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

Swiss Noema Pharma raises CHF54m in Series A financing
It is one of the largest Series A rounds in Europe: Led by Sofinnova Partners and Polaris Partners, rare neurological diseases start-up Noema Pharma...

Moderna to file for EU approval of mRNA-1273 vaccine
Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...